Using bacteria to reduce inflammation in ulcerative colitis
Bacterial targeting of the P-glycoprotein/endocannabinoid axis for reducing intestinal inflammation in ulcerative colitis
['FUNDING_FELLOWSHIP'] · UNIV OF MASSACHUSETTS MED SCH WORCESTER · NIH-10906113
This study is looking at how changing certain bacteria in the gut can help reduce inflammation for people with ulcerative colitis, aiming to find a safer and more natural way to support their health instead of just using traditional medications.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MASSACHUSETTS MED SCH WORCESTER (nih funded) |
| Locations | 1 site (WORCESTER, UNITED STATES) |
| Trial ID | NIH-10906113 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting specific bacteria can help reduce inflammation in the intestines of patients with ulcerative colitis (UC). The approach focuses on restoring a healthy balance of gut microbiota to improve the body's natural defenses against inflammation, rather than relying solely on traditional medications that can have significant side effects. By understanding the role of P-glycoprotein and endocannabinoids in intestinal health, the study aims to develop a novel treatment strategy that is both effective and low-risk for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ulcerative colitis who are seeking alternative treatment options.
Not a fit: Patients who do not have ulcerative colitis or those who are already responding well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients suffering from ulcerative colitis.
How similar studies have performed: Other research has shown promise in using microbiome-targeted therapies for inflammatory bowel diseases, indicating that this approach may be viable.
Where this research is happening
WORCESTER, UNITED STATES
- UNIV OF MASSACHUSETTS MED SCH WORCESTER — WORCESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SALLIS, BENJAMIN FIDELIUS — UNIV OF MASSACHUSETTS MED SCH WORCESTER
- Study coordinator: SALLIS, BENJAMIN FIDELIUS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bacterial Infections